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Abstract
Tumour budding in colorectal cancer is an important prognostic factor. A recent consensus conference elabo-
rated recommendations and key issues for future studies, among those the use of pan-cytokeratin stains,
especially in stage II patients. We report the first prospective diagnostic experience using pan-cytokeratin for
tumour budding assessment. Moreover, we evaluate tumour budding using pan-cytokeratin stains and disease-
free survival (DFS) in stage II patients. To this end, tumour budding on pan-cytokeratin-stained sections was
evaluated by counting the number of tumour buds in 10 high-power fields (0.238 mm2), then categorizing
counts as low/high-grade at a cut-off of 10 buds, in two cohorts. Cohort 1: prospective setting with 236
unselected primary resected colorectal cancers analysed by 17 pathologists during diagnostic routine. Cohort
2: retrospective cohort of 150 stage II patients with information on DFS. In prospective analysis of cohort 1,
tumour budding counts correlated with advanced pT, lymph node metastasis, lymphovascular invasion, peri-
neural invasion (all p< 0.0001), and distant metastasis (p5 0.0128). In cohort 2, tumour budding was an
independent predictor of worse DFS using counts [p50.037, HR (95% CI): 1.007 (1.0–1.014)] and the low-
grade/high-grade scoring approach [p5 0.02; HR (95% CI): 3.04 (1.2–7.77), 90.7 versus 73%, respectively].
In conclusion, tumour budding assessed on pan-cytokeratin slides is feasible in a large pathology institute and
leads to expected associations with clinicopathological features. Additionally, it is an independent predictor of
poor prognosis in stage II patients and should be considered for risk stratification in future clinical studies.
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Introduction
Tumour budding in colorectal cancers and other gas-
trointestinal tumours (pancreas, oesophagus) is rec-
ognized as an important prognostic factor [1]. In
April 2016, a panel of international experts met in
Bern, Switzerland to discuss the issue of the diag-
nostic implementation of tumour budding for
colorectal cancer and outlined a set of recommenda-
tions based on H&E stains and a three-tiered scoring
system [2]. These recommendations were meant as a
first step in a dynamic process which over time
would yield more evidence regarding some key
issues, especially the feasibility of pan-cytokeratin
stains in general and clinical relevance specifically
in stage II patients.
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A Swiss Association of Gastrointestinal Pathology
study published in 2016 focused on the inter-observer
reproducibility of budding counts on H&E and pan-
cytokeratin (AE1/AE3) sections across six different
institutes [3]. Several take-home messages were out-
lined: (1) tumour budding counts were three to six
times greater upon pan-cytokeratin staining compared
to H&E, (2) the inter-observer reproducibility was
markedly improved with pan-cytokeratin staining com-
pared to H&E and (3) a continuous count of the num-
ber of tumour buds in 1 or 10 hotspots outperformed a
categorical scoring system using a low/high-grade clas-
sification. Other authors have also underlined excellent
inter- and/or intra-observer agreement with pan-
cytokeratin staining in colon, oesophagus, pancreas, and
breast cancer as a fast method for tumour budding
assessment [4–7]. Based on these studies, the Institute
of Pathology, University of Bern has implemented
tumour budding counts into all diagnostic reports of
primary resected colon cancers from 2013 to 2016
using the 10-hotspot method on pan-cytokeratin.
Only a few studies to date have evaluated the associ-
ation of tumour budding with clinicopathological data
in the highly relevant subgroup of stage II patients
using pan-cytokeratin stains [1]. Recent data suggest
that stage II colorectal cancers are a particularly hetero-
geneous group of patients deriving little benefit from
post-operative chemotherapy in an unselected setting
[8]. Tumour budding has a major impact on the prog-
nostic stratification of patients with this disease and
may be an important parameter to identify high-risk
patients [9]. Indeed, several studies have shown the
impact of tumour budding on overall survival, but few
have addressed disease-free survival (DFS) in stage II
and only one until now has evaluated DFS and tumour
budding with pan-cytokeratin stains.
The aim of this study was to determine the per-
formance of pan-cytokeratin staining for the assess-
ment of tumour budding using a continuous count
and a low/high-grade scoring system in two different
relevant scenarios: (1) in diagnostic practice, prospec-
tively after more than 2 years of implementation as a
routine and (2) in a retrospective stage II collective
with the endpoint of DFS.
Methods
Prospective cohort (Institute of Pathology,
University of Bern, Switzerland)
From 2013 to 2016, 17 board certified pathologists,
including six gastrointestinal experts, evaluated
tumour budding counts on pan-cytokeratin (AE1/
AE3) stained sections of 236 surgically treated
colorectal cancers as part of daily diagnostic routine.
Peritumoural budding was defined as single cells or
small clusters of less than five cells ahead of the
invasive front. An average of six tumour blocks was
available per case (median: 5; range 1–14). The
block containing the largest number of buds was
selected on H&E staining and was immunostained
for AE1/AE3 (AE1/AE3; Dako, mouse monoclonal,
1:200, enzyme pre-treatment for 5 min, DAB chrom-
ogen) on a Leica Bond III instrument. After scanning
the tumour border at low power, 10 high-power fields
(403 HPFs, 0.238 mm2) of densest tumour budding
at the invasion front were scored and the total count
of tumour buds was recorded [4]. This number along
with the following clinicopathological information
were extracted from pathology reports: patient gen-
der, age at diagnosis, tumour size and location, histo-
logical subtype, pT, pN, pM (UICC seventh edition),
lymphatic (L) and venous (V) invasion, perineural
invasion (Pn), tumour grade, the number of positive
lymph nodes and the percentage of expansive (push-
ing) tumour border. A pan-cytokeratin stain for
tumour budding is shown in Figure 1. This cohort
was used to determine whether tumour budding
counts on AE1/AE3 in daily diagnostic practice
reflects the expected associations of higher counts
with more unfavourable prognostic features.
Retrospective cohort (Mount Sinai Hospital,
Toronto, Canada)
Case selection included consecutive cases (n5 181) of
primary colonic tumours and upper rectal tumours located
above the peritoneal reflection in their entirety with suffi-
cient archival material. All patients were treated at the
Mount Sinai Hospital between 1992 and 2010. Thirty-one
Figure 1. Pan-cytokeratin staining of colorectal cancer, high-
lighting epithelial cells in brown along with numerous tumour
buds at the invasion front.
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patients were excluded. Of these, 26 patients were
excluded due to death within 6 months of surgery or
follow-up of less than 3 years. Further, three pathological
stage II patients had clinical evidence of metastatic dis-
ease unknown to the pathologist. One patient had a
tumour in the pancreas which was thought clinically to
represent a second primary rather than a metastasis but
this was not proven. One patient had lung metastases
within 2 months of diagnosis and was likely to have had
stage IV disease from the outset. Final patient number was
150. All slides and gross descriptions were re-reviewed
according to the UICC TNM seventh edition by one gas-
trointestinal pathologist (AG). Clinical information was
retrieved from patient records. Mean and median follow
up were 63 and 62 months, respectively (min and max: 7–
176 months). No patients received neoadjuvant chemo-
therapy. Patients were followed up in accordance with
Cancer Care Ontario recommendations. Specimens were
fixed in 10% neutral buffered formalin. Gross assessment
and dissection was performed in accordance with standard
protocols. An average of six tumour blocks was sampled
per case (median: 5; range 1–16). Serial sections were cut
at 4-lm from archival tissue blocks and stained for H&E
and pan-cytokeratin (AE1/AE3; Dako, mouse monoclo-
nal, 1:200, enzyme pre-treatment 5 min, DAB chromo-
gen; using a Leica Bond Rx instrument). Tumour budding
was scored in the same manner as for the prospective
cohort, namely in 10 HPFs (403, 0.238 mm2) of densest
tumour budding at the invasion front. A total count across
these 10 fields was then obtained, until 250 buds. Four
pathologists or pathologists-in-training scored tumour
budding on 59 cases to determine the inter-observer agree-
ment (RK, HD, AG, BM). The aim of this cohort was to
determine the effect of tumour budding using the 10 HPF
method on pan-cytokeratin on disease-free survival in
stage II patients.
Inter-observer variability in block selection
To address inter-observer variability in block selec-
tion, a random set of 10 cases from cohort 1 was
selected. Two gastrointestinal pathologists (AL and
HD) independently reviewed the diagnostic H&E
slides and selected the optimal block for budding
assessment in a blinded fashion. For discrepant cases,
both pathologists were asked to score budding in
10 HPF using a cytokeratin-stained slide to investi-
gate whether the selection of different blocks would
strongly impact the budding score.
Statistics
This study was designed in accordance with the
REporting recommendations for tumour MARKer
prognostic studies (REMARK) [10]. Disease-free sur-
vival (DFS) was defined as the time from surgical
resection to local or distant recurrence or death,
whichever occurred first. Descriptive statistics were
performed for all budding counts. Pearson’s correla-
tion coefficient was used to determine the strength
of the linear relationship between budding counts
and continuous normally distributed data (r). The
association of tumour budding as a continuous vari-
able with categorical endpoints was analysed with
the Wilcoxon Rank Sum Test and with logistic
regression. Odds ratios (OR) and 95% confidence
intervals (CI) were used to determine effect size
with the least aggressive feature used as baseline
(OR 1.0). Receiver operating characteristic (ROC)
curve analysis and area under the curve (AUC) were
used to determine the discriminatory power of
tumour budding for the binary endpoint. The intra-
class correlation coefficient (ICC) and kappa value
(j) were used to determine the inter-observer agree-
ment in counts and categories, respectively. The
Kaplan-Meier method was used to represent survival
curves and the log-rank test was used to test signifi-
cant survival time differences. Multivariate survival
time models were analysed using continuous budding
counts with the hazard ratio (HR) of 1.0 as baseline
and 95% confidence intervals (CI). The Chi-Square
or Fisher’s Exact tests were used where appropriate.
Analyses were performed using SPSS (Version 21)
and with SAS (Version 9.4 SAS Institute, Cary,
NC). P values <0.05 were considered statistically
significant.
Ethics approval
According to the Swiss Law for Research on Humans
(Human Research Act, article 2, section 1c) the anon-
ymously collected data of the prospective cohort
(Institute of Pathology, University of Bern, Switzer-
land) does not fall under the scope of the Human
Research Act. Research ethics board approval was
obtained from Mount Sinai Hospital, Toronto for
analysis of the retrospective cohort (Mount Sinai
Hospital, Toronto, Canada).
Results
Prospective cohort
Two hundred and thirty-six cases were analysed.
Patient characteristics are found in Table 1. The aver-
age number of tumour buds was 76.9 across 10 HPFs
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(average 7.69 buds/HPF). The distribution of tumour
buds found across all patients ranged from 0 to 300.
Continuous counts of tumour buds
Table 1 highlights the OR (95% CI) for tumour bud-
ding and clinicopathological features. There was no
association between budding counts and age, gender,
tumour size, tumour location or histological subtype
of the tumour, nor with tumour grade, or resection
margin status. A significant and strong association
between a higher count of tumour buds was observed
with more advanced pT stage (pT1/2 versus pT3/4,
p< 0.0001; AUC5 0.7555; pT3 versus pT4, p5
0.0012), lymph node metastasis (p< 0.0001; AUC5
0.7258) and the number of positive lymph nodes (p<
0.0001, r5 0.31), venous (p< 0.0001; AUC50.7092)
and lymphatic invasion (p< 0.0001; AUC50.6858),
perineural invasion (p< 0.0001; AUC50.742) and
distant metastasis (p5 0.0128; AUC50.6872; Figure
2). An inverse correlation between the percentage of
expansive tumour border (pushing border) and tumour
budding counts was observed (p< 0.0001; r520.44).
Cut-off low/high-grade budding
Using a previously published cut-off of 10 buds to
assign a low- and high-grade budding score, 163
patients (69.1%) were considered low-grade and 73
(30.9%) were found to have high-grade budding.
Associations between the same features were observed
(Table 1), namely with pT stage [p< 0.0001; OR
(95% CI: 8.78 (3.05–25.3)], lymph node metastasis
[p< 0.0001; OR (95% CI): 3.74 (2.04–6.84)], lym-
phatic invasion [p< 0.0001; OR (95% CI): 3.68
(1.99–6.82)], vascular invasion [p< 0.0001; OR (95%
CI): 4.46 (2.66–8.07)], perineural invasion
(p< 0.0001; OR (95% CI): 5.41 (2.82–10.34)], distant
metastasis [p5 0.0022; OR (95% CI): 3.63 (1.53–
8.63)], the number of positive lymph nodes and inver-
sely with the percentage of expansive tumour border
(all P values <0.005).
Table 1. Associations between tumour budding counts and categories, and clinicopathological features, assessed prospectively during
daily diagnostic routine on pan-cytokeratin slides
Feature No.
Continuous counts Freq N (%)
P valueOR (95% CI) P value AUC Low n5 163 (69.1) High n5 73 (30.9)
Gender Male 144 1.0 0.3518 0.518 95 (58.3) 49 (67.1) 0.198
Female 92 0.998 (0.993–1.002) 68 (41.7) 24 (32.9)
Tumour location Left1 rectum 130 1.0 0.8571 0.502 90 (58.4) 40 (54.8) 0.6039
Right 97 1.0 (0.996–1.005) 64 (41.6) 33 (45.2)
Histological subtype Adenocarcinoma 207 1.0 141 (86.5) 66 (90.4) 0.398
Mucinous/other 29 0.998 (0.991–1.005) 0.544 0.53 22 (13.5) 7 (9.6)
pT pT1-2 59 1.0 <0.0001 0.71 55 (40.7) 4 (11.4) 0.0012
pT3-4 177 1.019 (1.01–1.028) 108 (59.3) 69 (88.6)
pT3 111 1.0 0.0012 0.659 80 (74.1) 31 (44.9) <0.0001
pT4 66 1.009 (1.003–1.014) 28 (25.9) 38 (55.1)
pN pN0 135 1.0 <0.0001 0.7258 119 (79.3) 37 (50.7) <0.0001
pN1-2 87 1.011 (1.006–1.016) 31 (20.7) 36 (49.3)
V V0 142 1.0 <0.0001 0.7092 116 (72.1) 26 (36.6) <0.0001
V1-2 90 1.013 (1.008–1.018) 45 (28.0) 45 (63.4)
L L0 106 1.0 <0.0001 0.6858 88 (54.7) 18 (24.7) <0.0001
L1-2 128 1.013 (1.007–1.018) 73 (45.3) 55 (75.3)
Pn Pn0 175 1.0 <0.0001 0.742 137 (86.2) 38 (53.5) <0.0001
Pn1 55 1.015 (1.009–1.021) 22 (13.8) 33 (46.5)
R R0 213 1.0 0.0852 0.595 149 (96.1) 64 (90.1) 0.0727
R1-2 13 1.007 (0.999–1.016) 6 (3.9) 7 (9.9)
Grade G1-2 187 1.0 0.9498 0.514 130 (83.9) 57 (82.6) 0.8143
G3 37 1.0 (0.994–1.006) 25 (16.1) 12 (17.4)
pM pM0 215 1.0 0.0128 0.6872 153 (93.9) 59 (80.8) 0.0022
pM1 21 1.009 (1.003–1.015) 10 (6.1) 14 (19.2)
Age 236 20.057 0.3794 – 113.6* 120.7* 0.4571
Tumour size 222 0.05 0.4275 – 110.3* 112.5* 0.8136
No. pos LN 221 0.31 <0.0001 – 101.1* 132.8* <0.0001
Expansive TBC 213 20.44 <0.0001 – 67.6* 125.5* <0.0001
*Test statistics from rank sum test.
pT, pathological T stage (TNM); pN, pathological lymph node status (TNM); V, venous invasion; L, lymphatic invasion; Pn, perineural invasion; R, resection status;
pM, pathological evidence of metastasis; No. pos LN, Number of positive lymph nodes; TBC, tumour border configuration.
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Table 2 compares the performance of both the con-
tinuous scores and cut-off scores regarding goodness-
of-fit of the logistic regression models used to ana-
lyse these results. A lower Akaike Information Crite-
rion (AIC) is interpreted as a better model fit and
may translate into more reliable data. In all cases, the
AIC values were lower in the analyses using a con-
tinuous budding count, implying a more reliable
model than using cut-off scores.
Retrospective stage II cohort
The 10 HPF method was applied to determine
tumour budding counts on 150 stage II patients. The
number of tumour buds across 10 HPFs was 71.1
(average: 7.11 buds per HPF), the median bud count
across 10 HPF was 53.5.
Continuous counts of tumour budding
The ICC value used to measure the inter-observer
agreement of tumour budding counts for four
observers was 0.79. No associations between continu-
ous tumour budding counts or low-/high-grade bud-
ding scores were noted with gender, pT3/pT4,
tumour location, tumour grade, perforation and the
presence of extra-mural venous invasion (EMVI),
although numbers for the latter three features are
likely underpowered (Table 3).
Figure 2. Receiver Operating Characteristic (ROC) curve analysis for tumour budding scores in 10 high power fields using pan-cytokeratin slides.
ROC-curves and corresponding area under the curve values for the identification of patients with (A) advanced tumour stage; (B) presence of
nodal metastasis; (C) presence of venous invasion; (D) lymphatic invasion; (E) perineural invasion; and (F) distant metastatic disease are shown.
Table 2. Comparison of goodness-of-fit (continuous and cut-off
scores) of models of tumour budding on pan-cytokeratin
Feature
Continuous budding counts Cut-off at 10 buds
AIC AIC
pT 229.309 243.426
pN 245.698 258.038
V 287.039 288.06
L 301.255 307.341
Pn 226.058 229.905
pM 150.423 150.561
AIC, Akaike Information Criterion; pT, pathological tumour stage (TNM); pN,
pathological lymph node status (TNM); V, venous invasion; L, lymphatic inva-
sion; Pn, perineural invasion; pM, pathological evidence of metastasis (TNM).
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Nonetheless, patients with greater counts of
tumour buds had a significantly shorter disease-free
survival time in univariate [p5 0.0382, HR (95%
CI): 1.006 (1.0–1.011)] and multivariable
[p5 0.037; HR (95% CI): 1.007 (1.0–1.014)] analy-
sis, adjusting for gender, pT, tumour location, and
EMVI (Table 4).
Cut-off low/high-grade budding
The kappa values used to measure the inter-observer
agreement between observers ranged from 0.61 to
0.83 in pairwise comparisons. Overall, agreement
between all four observers was j5 0.7 (0.51–0.87).
Using a cut-off score of 10 buds across 10 HPFs, we
found 104 (69.3%) patients with low-grade and 46
patients (30.7%) with high-grade budding. There
were no associations between tumour budding and
any of the clinicopathological features evaluated.
However, a significantly lower 5-year DFS was
found in patients with high-grade budding (73%)
compared to low-grade budding (90.7%; p5 0.0095;
Figure 3). Tumour budding status was again found to
be an independent prognostic factor in multivariable
analysis [p5 0.02; HR (95% CI): 3.04 (1.2–7.77);
Table 4] adjusting for potential confounders: gender
pT, tumour location, and EMVI.
Inter-observer variability in block selection
Two gastrointestinal pathologists (AL and HD) inde-
pendently reviewed the diagnostic H&E slides and
selected the optimal block for budding assessment in
a randomly selected set of 10 cases from cohort I.
The observers selected the same block for budding
assessment in 9 out of 10 cases. One case was dis-
cordant. For this case, both pathologists were asked
to score budding in 10 HPF using a cytokeratin-
stained slide to investigate whether the selection of
different blocks would strongly impact the budding
score. Adjusting for visual field size, final scores
Table 3. Association between tumour budding counts and categories with clinicopathological features in a retrospective stage II
cohort assessed on pan-cytokeratin slides
Feature Freq (%)
Buds
Mean P value
Buds Freq (%)
LG HG P value
Gender Female 62 (41.3) 70.1 0.8772 45 (43.3) 16 (36.4) 0.4353
Male 88 (58.7) 71.8 59 (56.7) 28 (63.6)
pT pT3 127 (85.2) 69.9 0.8076 89 (86.4) 36 (81.8) 0.475
pT4 (a/b) 22 (14.8) 80.7 14 (13.6) 8 (18.2)
Location Right 75 (50.0) 80.4 0.2026 49 (47.1) 24 (54.6) 0.4086
Left 75 (50.0) 61.8 55 (52.9) 20 (45.5)
Tumour grade G1-2 138 (92.0) 68.5 0.1712 98 (94.2) 40 (90.9) 0.4618
G3 12 (8.0) 100.4 6 (5.8) 4 (9.1)
Perforation No 143 95.3) 71.8 0.4435 99 (95.2) 42 (95.5) 1.0
Yes 7 (4.7) 56.3 5 (4.8) 2 (4.6)
EMVI No 121 (86.4) 70.0 0.1467 85 (87.6) 34 (82.9) 0.4638
Yes 19 (13.6) 86.2 12 (12.4) 7 (17.1)
LG, low grade; HG, high grade; pT, pathological tumour stage (TNM); G, grade; EMVI, extra-mural venous invasion.
Table 4. Multivariable analysis of disease-free survival in stage II patients with tumour budding counts and categories
Feature
Counts Cutoff
HR (95% CI) P value HR (95% CI) P value
Budding Baseline 1.0 0.037 LG 1.0 0.02
Bud count 1.007 (1.0–1.014) HG 3.04 (1.2–7.77)
Gender* Male 1.0 0.178 Male 1.0 0.24
Female 0.49 (0.17–0.38) Female 0.54 (0.19–1.52)
pT* pT3 1.0 0.465 pT3 1.0 0.366
pT4 1.55 (0.48–5.0) pT4 1.7 (0.54–5.42)
Tumour location* Right 1.0 0.355 Right 1.0 0.544
Left 1.37 (0.44–4.03) Left 1.35 (0.5–3.51)
EMVI No 1.0 0.855 V0 1.0 0.864
Yes 1.13 (0.31–4.06) V1 1.12 (0.31–4.0)
*Gender, pT and tumour location were all associated with disease-free survival in univariate analysis.
HR, hazard ratio; LG, low grade; HG, high grade; pT, pathological tumour stage (TNM); V, venous invasion; EMVI, extra-mural venous invasion.
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correlated well, with an average of 9.8 buds and 11.5
buds per HPF, respectively.
Discussion
The novel findings of this study underscore that the
use of pan-cytokeratin (AE1/AE3) immunostaining
for the evaluation of tumour budding is feasible in
daily diagnostic practice and that DFS in stage II
patients can be stratified by tumour budding assessed
using this method.
As tumour budding on slides immunostained for
pan-cytokeratin evaluated using a 10 HPF method [4]
has been used at our institute for more than 2 years,
we have for the first time the opportunity to deter-
mine the effect of tumour budding in a prospective
setting. An association between higher counts of
tumour buds, as recorded in diagnostic reports, and
more aggressive tumour features was seen, as
expected. The use of cytokeratin for the assessment
of tumour budding has several advantages over H&E
staining. First, immunostaining unmasks three to six
times more tumour buds than H&E, better reflecting
the biology of the tumour at the invasion front [3].
Fewer buds are being missed in regions of dense
peritumoural inflammation and a better discrimina-
tion from activated fibroblasts can be made. Patholo-
gists who are less experienced with tumour budding
feel more confident with immunostaining and the
overall impression given by pathologists is that it is
quicker. Reliability is objectively reflected in the
greater inter-observer agreement that can be reached
with cytokeratin in comparison to H&E [3]. Whether
a continuous or categorical scoring system is being
applied, tumour budding counts between pathologists
are significantly more reproducible with cytokeratin
staining. We also provide evidence that selection of
blocks for cytokeratin staining is reproducible and
consistent between different observers. Taken
together, these arguments support the use of pan-
cytokeratin for the daily reporting of tumour budding
in colorectal cancer.
In a previous study on stage II colorectal cancer,
we evaluated the inter-observer reproducibility of
tumour budding counts on pan-cytokeratin slides
using various scoring systems and the association of
tumour budding with overall survival [11]. We
showed that continuous budding counts led to a
stronger inter-observer agreement. The novel findings
of this study demonstrate, using statistical methods,
that although the same associations were identified
using counts or categories, continuous counts provide
better goodness-of-fit to our statistical models. Addi-
tionally, observing the ROC curve of tumour budding
for all relevant endpoints, no single threshold value
should be preferred to split tumour budding counts
into low and high groups. The distribution of tumour
buds across the range of values also provides no hint
for a useful/appropriate threshold value. Several addi-
tional arguments supporting a continuous count of
tumour buds can be made: the probability of having
a clinically relevant outcome (such as lymph node
metastasis) will increase as the number of tumour
buds increases [9]. Also, if the cut-off 10 buds are
used, it seems unreasonable to suggest that tumours
with 9 or 11 buds are biologically sufficiently differ-
ent that they should be placed in different categories.
Indeed, from a clinical standpoint, cut-offs are fre-
quently applied to continuous variables in pathology
practice despite their limitations (tumour grade, lym-
phovascular invasion). To benefit from both types of
data, both the number of tumour buds and a corre-
sponding category (low-grade, high-grade) could be
reported.
Regardless of the scoring method, tumour budding
assessed by cytokeratin was a significant and inde-
pendent factor in DFS analysis in stage II patients.
Several other authors, using H&E staining, have high-
lighted similar results in stage II CRC (reviewed in
[9]). Using a modified Ueno method on H&E stain
(area 0.95 mm2; high-grade budding defined as 10
buds), Betge et al found high-grade tumour budding
to be associated with significantly worse DFS in a
Figure 3. Kaplan-Meier curve and log-rank test highlighting
survival time differences in patients with low- and high-grade
tumour budding on pan-cytokeratin staining in 150 stage II
colorectal cancer patients.
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series of 120 patients (65 versus 91%, high- versus
low-grade budding, respectively) [12]. Our study using
the 10 HPFs method incorporating densest hotspots
has also outlined very similar DFS rates (90.7 and
70.3%) for low-grade and high-grade budding.
Although this appears to be the first study to eval-
uate pan-cytokeratin staining for the evaluation of
tumour budding in a prospective diagnostic setting,
these results may be limited by a potential bias,
namely that pathologists were not blinded to the
TNM stage of the disease or other clinicopathological
features at the time of budding counts. Nonetheless,
our results demonstrate that even in a setting where
tumour budding is reviewed by a multitude of pathol-
ogists, it is useful as a prognostic parameter.
To conclude, assessment of tumour budding on pan-
cytokeratin slides is feasible in a large pathology insti-
tute and leads to expected associations with clinicopa-
thological features. Additionally, it is an independent
factor of poor prognosis in stage II patients and should
be considered in future studies on tumour budding.
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